BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 35363853)

  • 1. Epithelial-Mesenchymal Plasticity in Tumor Immune Evasion.
    Mullins RDZ; Pal A; Barrett TF; Heft Neal ME; Puram SV
    Cancer Res; 2022 Jul; 82(13):2329-2343. PubMed ID: 35363853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epithelial-Mesenchymal Plasticity in Cancer Progression and Metastasis.
    Lu W; Kang Y
    Dev Cell; 2019 May; 49(3):361-374. PubMed ID: 31063755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revisiting epithelial-mesenchymal transition in cancer metastasis: the connection between epithelial plasticity and stemness.
    Liao TT; Yang MH
    Mol Oncol; 2017 Jul; 11(7):792-804. PubMed ID: 28649800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
    Jiang Y; Zhan H
    Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial-to-Mesenchymal Transition in the Light of Plasticity and Hybrid E/M States.
    Bornes L; Belthier G; van Rheenen J
    J Clin Med; 2021 May; 10(11):. PubMed ID: 34072345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on Epithelial-Mesenchymal Plasticity in Cancer Progression.
    Fontana R; Mestre-Farrera A; Yang J
    Annu Rev Pathol; 2024 Jan; 19():133-156. PubMed ID: 37758242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EMT-induced immune evasion: connecting the dots from mechanisms to therapy.
    Imodoye SO; Adedokun KA
    Clin Exp Med; 2023 Dec; 23(8):4265-4287. PubMed ID: 37966552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas.
    Jolly MK; Somarelli JA; Sheth M; Biddle A; Tripathi SC; Armstrong AJ; Hanash SM; Bapat SA; Rangarajan A; Levine H
    Pharmacol Ther; 2019 Feb; 194():161-184. PubMed ID: 30268772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The epithelial-mesenchymal plasticity landscape: principles of design and mechanisms of regulation.
    Haerinck J; Goossens S; Berx G
    Nat Rev Genet; 2023 Sep; 24(9):590-609. PubMed ID: 37169858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Immune Microenvironment during Epithelial-Mesenchymal Transition.
    Taki M; Abiko K; Ukita M; Murakami R; Yamanoi K; Yamaguchi K; Hamanishi J; Baba T; Matsumura N; Mandai M
    Clin Cancer Res; 2021 Sep; 27(17):4669-4679. PubMed ID: 33827891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosuppressive Traits of the Hybrid Epithelial/Mesenchymal Phenotype.
    Sahoo S; Nayak SP; Hari K; Purkait P; Mandal S; Kishore A; Levine H; Jolly MK
    Front Immunol; 2021; 12():797261. PubMed ID: 34975907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Computational Systems Biology Approach Identifies SLUG as a Mediator of Partial Epithelial-Mesenchymal Transition (EMT).
    Subbalakshmi AR; Sahoo S; Biswas K; Jolly MK
    Cells Tissues Organs; 2022; 211(6):689-702. PubMed ID: 33567424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EMT Transition States during Tumor Progression and Metastasis.
    Pastushenko I; Blanpain C
    Trends Cell Biol; 2019 Mar; 29(3):212-226. PubMed ID: 30594349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epithelial-to-mesenchymal transition in cancer progression: unraveling the immunosuppressive module driving therapy resistance.
    Singh D; Siddique HR
    Cancer Metastasis Rev; 2024 Mar; 43(1):155-173. PubMed ID: 37775641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolating and targeting the real-time plasticity and malignant properties of epithelial-mesenchymal transition in cancer.
    Esquer H; Zhou Q; Nemkov T; Abraham AD; Rinaldetti S; Chen YC; Zhang X; Orman MV; D'Alessandro A; Ferrer M; Messersmith WA; LaBarbera DV
    Oncogene; 2021 Apr; 40(16):2884-2897. PubMed ID: 33742123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging Concepts of Hybrid Epithelial-to-Mesenchymal Transition in Cancer Progression.
    Sinha D; Saha P; Samanta A; Bishayee A
    Biomolecules; 2020 Nov; 10(11):. PubMed ID: 33207810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging roles of epithelial-mesenchymal plasticity in invasion-metastasis cascade and therapy resistance.
    Garg M
    Cancer Metastasis Rev; 2022 Mar; 41(1):131-145. PubMed ID: 34978017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Epithelial-Mesenchymal Transition in Tumor Progression.
    Gloushankova NA; Zhitnyak IY; Rubtsova SN
    Biochemistry (Mosc); 2018 Dec; 83(12):1469-1476. PubMed ID: 30878022
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Canciello A; Cerveró-Varona A; Peserico A; Mauro A; Russo V; Morrione A; Giordano A; Barboni B
    Front Cell Dev Biol; 2022; 10():1038841. PubMed ID: 36467417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controversies around epithelial-mesenchymal plasticity in cancer metastasis.
    Williams ED; Gao D; Redfern A; Thompson EW
    Nat Rev Cancer; 2019 Dec; 19(12):716-732. PubMed ID: 31666716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.